Small Intestine Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Small Intestine Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Small intestine cancer, a rare malignancy, originates when malignant cells form in the tissues of the small intestine. This vital organ, composed of diverse cell types, gives rise to various cancer types. Adenocarcinomas, arising from gland cells lining the intestine, constitute approximately one-third of small intestine cancers. Carcinoid tumors, a subtype of neuroendocrine tumors, are generally slow-growing and the most prevalent small intestine tumors. Lymphomas, originating in lymphocytes, can manifest in the small intestine, while sarcomas, starting in connective tissues like muscle, include gastrointestinal stromal tumors (GISTs). Understanding these distinct types is crucial for accurate diagnosis and tailored treatment approaches.
The Small Intestine Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Small Intestine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small Intestine Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Small Intestine Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Small Intestine Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Small Intestine Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Small Intestine Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aprea Therapeutics IncBeijing Immunochina Pharmaceuticals Co Ltd
CytomX Therapeutics Inc
Duality Biologics (Shanghai) Co Ltd
Exelixis Inc
Genentech USA Inc
Genexine Inc
Jacobio Pharmaceuticals Group Co Ltd
Johnson & Johnson
Loxo Oncology Inc
Merck & Co Inc
MiNK Therapeutics Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Osaka University
PDS Biotechnology Corp
Revolution Medicines Inc
Shanghai Miracogen Inc
Shenzhen Zhenxing Pharmaceutical Technology
Virogin Biotech Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Small Intestine Cancer reports